According to the letter, the FDA did not agree with the proposition to include additional extended dosing intervals greater than 16 weeks. The Food and Drug Administration (FDA) has issued a ...

Background To investigate the short-term outcomes of treatment with intravitreal aflibercept in cases with wet age-related macular degeneration (AMD) resistant to ranibizumab. Methods The study ...